The North Texas RCIC had the opportunity to meet with Johnson & Johnson (J&J COSAT) before the holidays and would like to pass along an important Life Science Funding Opportunity for North Texas.

Their interests include: medical devices, diagnostics, biotechnology, and consumer products. On a periodic basis, the emerging technologies group within J&J COSAT organizes a day to review early stage opportunities to consider such opportunities for a non-dilutive seed grant funding program. The awardees could potentially benefit from this program in several ways:
seed (non-dilutive) funding, which is usually capped at around $250K;
access to J&J’s internal experts in a relevant domain; and
enhanced visibility in the investment community by virtue of J&J’s support.
Click here for details